A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...
Allen was diagnosed with Non-Hodgkin Lymphoma in December, but he seems to be in the home stretch of treatment.
Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...
A new wave of immuno-therapies is reshaping the fight against cancer, turning the body’s own immune system into a powerful ...
The FDA has approved nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adult and pediatric patients age 12 and older with treatment-naiv ...
The friends and family of an ‘amazing’ and ‘inspiring’ woman who died from a brain tumour are taking on the Lewes Three Peaks challenge to raise money for The Royal Marsden Cancer Charity.
In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and ...
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) ...
FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...
Opdivo has received new approvals in the United States and European Union for use in classical Hodgkin Lymphoma across adult and pediatric patients. The expanded indications cover newly diagnosed and ...
Although survival rates for acute myeloid leukemia (AML) continue to improve, many long-term survivors face persistent physical limitations, high rates of comorbidities, and suboptimal lifestyle ...
According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results